RecruitingNCT04904146
Rare condition
Sézary syndrome
9
studies recruiting now
as of 7 Sept 2026
34
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
19 Sept 2024
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT04256018
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
RecruitingPhase 2NCT05996185
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
RecruitingNCT05157581
Extracorporeal Photopheresis in Sezary Syndrome
RecruitingNCT06588868
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 9 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Sézary syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Sézary syndrome
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (CTLA4, TNFRSF1B, CD28).
Treatments being studied
1 approved treatment and 9 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Mogamulizumab (Poteligeo)
Phase 3Zanolimumab (Humax-cd4)
Phase 2Methoxsalen (8-mop)
Phase 2Pembrolizumab (Keytruda)
Phase 2Doxycycline (Doxirobe)
Phase 2Nelarabine (Arranon)
Phase 2Alemtuzumab (Campath mabcampath)
Phase 2Atezolizumab (Atezolizumab component of tecentriq hybreza)
Phase 1Ciaftalan
+ 1 more in development
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).